

Yiping Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10006981/publications.pdf>

Version: 2024-02-01

97
papers

7,526
citations

186265

28
h-index

58581

82
g-index

113
all docs

113
docs citations

113
times ranked

7352
citing authors

#	ARTICLE	IF	CITATIONS
1	Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial. <i>Clinical Cancer Research</i> , 2022, 28, 461-467.	7.0	24
2	The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1693-1703.	4.2	18
3	On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial. <i>Molecular Cancer</i> , 2022, 21, 4.	19.2	28
4	Pharmacist-Led Management Improves Treatment Adherence and Quality of Life in Opioid-Tolerant Patients With Cancer Pain: A Randomized Controlled Trial. <i>Pain and Therapy</i> , 2022, 11, 241-252.	3.2	1
5	A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China. <i>Targeted Oncology</i> , 2022, 17, 1-13.	3.6	6
6	Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 25.	17.1	12
7	Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial. <i>BMC Medicine</i> , 2022, 20, 42.	5.5	26
8	Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2022, 165, 71-81.	2.0	9
9	A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors. <i>Lung Cancer</i> , 2022, 166, 98-106.	2.0	1
10	Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2). <i>Nature Communications</i> , 2022, 13, 857.	12.8	50
11	Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (Camel-Sq): A Phase 3 Trial. <i>Journal of Thoracic Oncology</i> , 2022, 17, 544-557.	1.1	114
12	Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial. <i>BMC Medicine</i> , 2022, 20, 154.	5.5	7
13	Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study. <i>BMC Pulmonary Medicine</i> , 2022, 22, 179.	2.0	5
14	A phase II trial of ALK/ROS1 tyrosine kinase inhibitor WX-0593 (iruplinalkib) in ALK-positive and crizotinib-resistant advanced non-small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 9073-9073.	1.6	1
15	Abstract CT505: Phase I study of D-1553 to assess safety and efficacy in patients with non-small cell lung cancer (NSCLC) harboring KRASG12C mutation. <i>Cancer Research</i> , 2022, 82, CT505-CT505.	0.9	1
16	The Clinical Efficacy and Economic Benefits of Recombinant Human Thrombopoietin for the Treatment of Chemotherapy or Chemoradiotherapy-Induced Thrombocytopenia. <i>Contrast Media and Molecular Imaging</i> , 2022, 2022, 1-7.	0.8	3
17	Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer (Camel): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 305-314.	10.7	277
18	Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078). <i>Lung Cancer</i> , 2021, 152, 7-14.	2.0	40

#	ARTICLE	IF	CITATIONS
19	Clinical efficacy and safety of mectapegfilgrastim in small cell lung cancer as primary prophylaxis of neutropenia post chemotherapy: a retrospective analysis. <i>Annals of Palliative Medicine</i> , 2021, 10, 7841-7846.	1.2	3
20	Genomic profiles and tumor immune microenvironment of primary lung carcinoma and brain oligo-metastasis. <i>Cell Death and Disease</i> , 2021, 12, 106.	6.3	16
21	Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050). <i>Lung Cancer</i> , 2021, 154, 176-185.	2.0	18
22	First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4049-4049.	1.6	19
23	Progression pattern and post-progression treatment of furmonertinib (AST2818) in EGFR T790M mutation positive NSCLC patients: A post-hoc analysis from a multicenter, single-arm study.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21071-e21071.	1.6	0
24	ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4000-4000.	1.6	25
25	Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing. <i>Journal of Thoracic Oncology</i> , 2021, 16, 827-839.	1.1	24
26	Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small cell lung cancer: A multicenter, randomized, double-blind, phase III trial. <i>Cancer Communications</i> , 2021, 41, 889-903.	9.2	16
27	Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1403-1414.	1.1	26
28	Treatment and Prognosis of Solid and Cystic Brain Metastases in Patients with Non-Small-Cell Lung Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 6309-6317.	1.9	7
29	Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 829-839.	10.7	66
30	Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 916.	7.4	310
31	Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 45-53.	10.7	105
32	Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 572853.	2.8	15
33	Safety and efficacy of aprepitant as mono and combination therapy for the prevention of emetogenic chemotherapy-induced nausea and vomiting: post-marketing surveillance in China. <i>Chinese Clinical Oncology</i> , 2020, 9, 68-68.	1.2	4
34	Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , 2020, 21, 832-842.	10.7	350
35	Gene Alterations in Paired Supernatants and Precipitates from Malignant Pleural Effusions of Non-Squamous Non-Small Cell Lung Cancer. <i>Translational Oncology</i> , 2020, 13, 100784.	3.7	13
36	PD-L1 expression in malignant pleural effusion samples and its correlation with oncogene mutations in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 1385-1392.	1.4	12

#	ARTICLE	IF	CITATIONS
37	Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT) Tj ETQq1 1 0.784314 rgBT /Overloc 8, 1132-1143.	10.7	169
38	A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer â€” The FALUCA study. Lung Cancer, 2020, 146, 252-262.	2.0	12
39	Pyrotinib in <i>HER2</i>-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study. Journal of Clinical Oncology, 2020, 38, 2753-2761.	1.6	123
40	Long-term safety of icotinib in patients with non-small cell lung cancer: a retrospective, real-world study. Journal of Thoracic Disease, 2020, 12, 639-650.	1.4	6
41	Efficacy and safety of aflutinib (AST2818) in patients with T790M mutation-positive NSCLC: A phase IIb multicenter single-arm study.. Journal of Clinical Oncology, 2020, 38, 9602-9602.	1.6	10
42	Cytological-negative pleural effusion can be an alternative liquid biopsy media for detection of EGFR mutation in NSCLC patients. Lung Cancer, 2019, 136, 23-29.	2.0	15
43	<p>The efficacy and safety of anlotinib treatment for advanced lung cancer</p>. OncoTargets and Therapy, 2019, Volume 12, 6549-6554.	2.0	24
44	Intracavitary chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is not superior to TKI monotherapy in controlling malignant pleural effusion recurrence in EGFR-mutated lung cancer patients. Journal of Thoracic Disease, 2019, 11, 3712-3720.	1.4	3
45	A randomised, multicentre open-label phase II study to evaluate the efficacy, tolerability and pharmacokinetics of oral vinorelbine plus cisplatin versus intravenous vinorelbine plus cisplatin in Chinese patients with chemotherapy-naïve unresectable or metastatic non-small cell lung cancer. Journal of Thoracic Disease, 2019, 11, 3347-3359.	1.4	5
46	Liquid biopsies using pleural effusion-derived exosomal DNA in advanced lung adenocarcinoma. Translational Lung Cancer Research, 2019, 8, 392-400.	2.8	24
47	CMAB009 plus irinotecan versus irinotecanâ€”only as secondâ€”line treatment after fluoropyrimidine and oxaliplatin failure in <i>KRAS</i> wildâ€”type metastatic colorectal cancer patients: promising findings from a prospective, openâ€”label, randomized, phase III trial. Cancer Communications, 2019, 39, 1-13.	9.2	6
48	Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respiratory Medicine,the, 2019, 7, 437-446.	10.7	192
49	Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. Journal of Thoracic Oncology, 2019, 14, 867-875.	1.1	260
50	Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, 989-999.	2.8	28
51	De Novo MET Amplification in Chinese Patients With Nonâ€”Small-Cell Lung Cancer and Treatment Efficacy With Crizotinib: A Multicenter Retrospective Study. Clinical Lung Cancer, 2019, 20, e171-e176.	2.6	22
52	Single-arm, phase II study of pyrotinib in advanced non-small cell lung cancer (NSCLC) patients with HER2 exon 20 mutation.. Journal of Clinical Oncology, 2019, 37, 9089-9089.	1.6	16
53	Distinct resistant mechanism and genomic evolution during TKI treatment in non-small cell lung cancer patients with or without acquired T790M mutation.. Journal of Clinical Oncology, 2019, 37, e20603-e20603.	1.6	0
54	Efficacy and safety of IBI305 compared with bevacizumab in advanced non-squamous NSCLC patients as first-line treatment in a randomized, double-blind, phase III study.. Journal of Clinical Oncology, 2019, 37, 9095-9095.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer. Lung Cancer, 2018, 118, 57-61.	2.0	39
56	Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTERO302). British Journal of Cancer, 2018, 118, 654-661.	6.4	192
57	Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing) Tj ETQq1 1 0.784314 rgBT /Overlock 10 lung cancer. Investigational New Drugs, 2018, 36, 315-322.	2.6	42
58	Efficacy and Safety of High-Dose Controlled-Release Oxycodone in the Treatment of Moderate to Severe Pain in Patients with Advanced Cancer: A Retrospective Study. Medical Science Monitor, 2018, 24, 0-0.	1.1	1
59	Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated NSCLC patients who develop brain metastasis. Archives of Medical Science, 2018, 14, 1298-1307.	0.9	28
60	China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016) Tj ETQq0 0,0 rgBT /Overlock 10	1.1	34
61	A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR TKI resistance. Cancer Medicine, 2017, 6, 154-162.	2.8	82
62	MET Gene Amplification and Overexpression in Chinese Non-Small-Cell Lung Cancer Patients Without EGFR Mutations. Clinical Lung Cancer, 2017, 18, 213-219.e2.	2.6	13
63	Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients. Cancer Biology and Therapy, 2017, 18, 883-887.	3.4	14
64	Salvage treatment with apatinib for advanced non-small-cell lung cancer. OncoTargets and Therapy, 2017, Volume 10, 1821-1825.	2.0	59
65	ALK and ROS1 rearrangements, coexistence and treatment in epidermal growth factor receptor-wild type lung adenocarcinoma: a multicenter study of 732 cases. Journal of Thoracic Disease, 2017, 9, 3919-3926.	1.4	24
66	A phase III trial (ZJBIO009): CMAB009 plus irinotecan versus irinotecan alone as second-line treatment after fluoropyrimidine and oxaliplatin failure in wild-type K-ras metastatic colorectal cancer patients.. Journal of Clinical Oncology, 2017, 35, 3513-3513.	1.6	0
67	Treatment and prognosis after progression in long-term responders to EGFR-tyrosine kinase inhibitor in advanced non-small cell lung cancer. Archives of Medical Science, 2016, 1, 107-111.	0.9	5
68	Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing. Oncotarget, 2016, 7, 61755-61763.	1.8	29
69	Rare frequency of gene variation and survival analysis in thymic epithelial tumors. OncoTargets and Therapy, 2016, Volume 9, 6337-6342.	2.0	9
70	Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor. OncoTargets and Therapy, 2016, 9, 211.	2.0	7
71	Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma. Cancer Medicine, 2016, 5, 2694-2700.	2.8	26
72	Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma. Lung Cancer, 2016, 99, 166-171.	2.0	49

#	ARTICLE	IF	CITATIONS
73	Patients with <sc>ROS</sc>1 rearrangementâ€positive nonâ€smallâ€cell lung cancer benefit from pemetrexedâ€based chemotherapy. <i>Cancer Medicine</i> , 2016, 5, 2688-2693.	2.8	35
74	Clinicopathologic characteristics, genetic variability and therapeutic options of RET rearrangements patients in lung adenocarcinoma. <i>Lung Cancer</i> , 2016, 101, 16-21.	2.0	32
75	Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma. <i>Journal of Translational Medicine</i> , 2016, 14, 188.	4.4	72
76	<i>HER2</i> mutations in Chinese patients with non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 78152-78158.	1.8	22
77	A retrospective analysis of the ICOGEN clinical trial demonstrates the utility of VeriStrat to predict outcome in an all Chinese cohort treated with EGFR TKI.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20626-e20626.	1.6	0
78	Chemotherapy and prognosis in advanced thymic carcinoma patients. <i>Clinics</i> , 2015, 70, 775-780.	1.5	16
79	Platinumâ€based chemotherapy plus cetuximab firstâ€line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an openâ€label, singleâ€arm, multicenter trial. <i>Head and Neck</i> , 2015, 37, 1081-1087.	2.0	22
80	Efficacy of gefitinib or erlotinib in patients with squamous cell lung cancer. <i>Archives of Medical Science</i> , 2015, 1, 164-168.	0.9	13
81	Second-line docetaxel-based chemotherapy after failure of fluorouracil-based first-line treatment for advanced esophageal squamous cell carcinoma. <i>OncoTargets and Therapy</i> , 2014, 7, 1875.	2.0	14
82	Docetaxelâ€based chemotherapy as secondâ€line regimen for advanced thymic carcinoma. <i>Thoracic Cancer</i> , 2014, 5, 169-173.	1.9	6
83	Primary neuroendocrine tumors of the thymus: Clinical review of 22 cases. <i>Oncology Letters</i> , 2014, 8, 2125-2129.	1.8	10
84	Treatment and prognosis of type B2 thymoma. <i>World Journal of Surgical Oncology</i> , 2014, 12, 291.	1.9	11
85	Brain Metastases from Esophageal Cancer: Clinical Review of 26 Cases. <i>World Neurosurgery</i> , 2014, 81, 131-135.	1.3	46
86	Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 591-595.	1.5	21
87	A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2014, 86, 207-212.	2.0	47
88	Retreatment with pemetrexed chemotherapy in advanced non-small cell lung cancer patient. <i>Journal of Thoracic Disease</i> , 2014, 6, 856-60.	1.4	4
89	Efficacy and safety of icotinib in Chinese patients with advanced non-small cell lung cancer after failure of chemotherapy. <i>Chinese Medical Journal</i> , 2014, 127, 266-71.	2.3	7
90	Efficacy of chemotherapy plus gefitinib treatment in advanced non-small-cell lung cancer patients following acquired resistance to gefitinib. <i>Molecular and Clinical Oncology</i> , 2013, 1, 875-878.	1.0	4

#	ARTICLE	IF	CITATIONS
91	Safety and efficacy results of a phase IV, open-label, multicenter, safety-monitoring study of icotinib in treating advanced non-small cell lung cancer (NSCLC): ISAFE study.. Journal of Clinical Oncology, 2013, 31, e19161-e19161.	1.6	3
92	Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with <i>EGFR</i> mutation-positive advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2012, 30, 7520-7520.	1.6	40
93	A phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens.. Journal of Clinical Oncology, 2012, 30, 7548-7548.	1.6	42
94	Final overall survival and updated biomarker analysis results from the randomized phase III ICOGEN trial.. Journal of Clinical Oncology, 2012, 30, 7559-7559.	1.6	4
95	Randomized phase II study of recombinant human endostatin in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer (NCT00912392).. Journal of Clinical Oncology, 2012, 30, 7091-7091.	1.6	0
96	Epidermal growth factor receptor mutation in small cell lung cancer patients detected by mutant-enriched liquidchip technology from plasma in China.. Journal of Clinical Oncology, 2012, 30, e17512-e17512.	1.6	0
97	Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncology, The, 2011, 12, 735-742.	10.7	3,758